文献速递精神分裂症与精神病性障碍

精神分裂症年轻患者糖尿病的内源性及抗精神病药相关风险:丹麦人群队列研究

Endogenous and Antipsychotic-Related Risks for Diabetes Mellitus in Young People With Schizophrenia: A Danish Population-Based Cohort Study.
PubMed 文献 · Am J Psychiatry · 2017-01-20

该丹麦全国队列研究随访1977年后出生人群至2013年,发现抗精神病药未暴露的精神分裂症患者糖尿病风险显著高于一般人群(调整后HR 3.07),起始抗精神病药治疗后风险进一步升高(调整后HR 3.64),且第一代与第二代抗精神病药风险相似。

要点

  • 抗精神病药未暴露的精神分裂症患者糖尿病风险已显著升高。
  • 起始抗精神病药治疗使糖尿病风险进一步增加。
  • 第一代与第二代抗精神病药升高糖尿病风险无显著差异。

核心结论

  • 精神分裂症本身带来高糖尿病内源性风险,第一代和第二代抗精神病药均进一步增加该风险。
  • 无论是否暴露于抗精神病药,均应早期发现和有效治疗糖尿病。

研究设计与样本

  • 丹麦全国基于人群的队列研究,随访1977年1月1日及以后出生者至2013年1月1日,共2,736,510人。
  • 使用丹麦精神病中央研究登记处确定精神分裂症诊断,丹麦国家处方登记处获取抗精神病药处方,丹麦国家患者登记处和处方登记处确定糖尿病。
  • 采用Cox比例风险回归模型估计内源性和抗精神病药相关糖尿病风险,并校正潜在混杂因素。

主要发现

  • 随访期间14,118人(0.52%)发生糖尿病,8,945人(0.33%)发生精神分裂症,总随访49,582,279人年。
  • 抗精神病药未暴露的精神分裂症患者相比一般人群,糖尿病调整后风险比3.07(95%CI 1.71-5.41)。
  • 起始抗精神病药治疗后糖尿病风险显著高于未暴露的精神分裂症患者,调整后风险比3.64(95%CI 1.95-6.82)。
  • 一线治疗使用第一代抗精神病药调整后风险比3.06(95%CI 1.32-7.05),第二代抗精神病药调整后风险比3.44(95%CI 1.73-6.83),两者无统计学显著差异。
  • 限于2型糖尿病的敏感性分析结果与主要结果一致。

临床怎么用

  • 精神分裂症患者无论是否使用抗精神病药,均应将糖尿病早期检测和有效治疗作为多学科管理组成部分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Diabetes mellitus contributes to excessive cardiovascular deaths and reduced life expectancy in schizophrenia. This population-based cohort study investigated the endogenous risk for diabetes in antipsychotic-naive schizophrenia and evaluated the risks added by starting antipsychotic treatment in people with schizophrenia. METHOD: The study followed all people born in Denmark on or after Jan. 1, 1977, until Jan. 1, 2013 (N=2,736,510). The Danish Psychiatric Central Research Register ascertained schizophrenia diagnoses. The Danish National Prescription Registry provided data on prescriptions of antipsychotics. Diabetes was ascertained from the Danish National Patient Register and Danish National Prescription Registry. The authors estimated the endogenous and antipsychotic-related risks for diabetes by using Cox proportional hazards regression models, while accounting for potential confounders. RESULTS: Of the cohort members, 14,118 (0.52%) developed diabetes, and 8,945 (0.33%) developed schizophrenia during follow-up (49,582,279 person-years). The adjusted hazard ratio for diabetes was 3.07 (95% confidence interval [CI], 1.71-5.41) in antipsychotic-naive schizophrenia compared with the general population. The risk for diabetes after starting antipsychotic treatment was significantly higher (adjusted hazard ratio, 3.64; 95% CI, 1.95-6.82) than the risk in antipsychotic-naive schizophrenia, after adjustment for family history of diabetes and other potential confounders. First-line treatment with either first-generation antipsychotics (adjusted hazard ratio, 3.06; 95% CI, 1.32-7.05) or second-generation antipsychotics (adjusted hazard ratio, 3.44; 95% CI, 1.73-6.83) increased the risk for diabetes without a statistically significant difference. Appropriate sensitivity analyses limited to type 2 diabetes corroborated these results. CONCLUSIONS: Schizophrenia confers a high endogenous risk for diabetes, and the risk is further increased by both first-generation and second-generation antipsychotics. Early detection and effective treatment of diabetes should be an integral part of multidisciplinary management of schizophrenia regardless of antipsychotic drug exposure.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Rajkumar AP, Horsdal HT, Wimberley T, et al. Endogenous and Antipsychotic-Related Risks for Diabetes Mellitus in Young People With Schizophrenia: A Danish Population-Based Cohort Study. Am J Psychiatry. 2017. PMID: 28103712. doi:10.1176/appi.ajp.2016.16040442

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。